Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores

Lenert, Leslie; Sturley, Ann; Rapaport, Mark Hyman; Chavez, Samantha de la Mora; Mohr, Penny; Rupnow, Marcia F.T.

doi:10.1016/j.schres.2003.10.010

Cited by 102 publications

(93 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[26] to group patients with schizophrenia into eight health states, based on the type and severity of symptoms experienced. Disease symptoms were grouped into three factors: negative (PANSS items G7, G16, N1–4 and N6), positive (G9, P1, P3, P5 and P6) and cognitive (G5, G10–13, G15, P2 and N5) [26].…”

Section: Methodsmentioning

confidence: 99%

“…Disease symptoms were grouped into three factors: negative (PANSS items G7, G16, N1–4 and N6), positive (G9, P1, P3, P5 and P6) and cognitive (G5, G10–13, G15, P2 and N5) [26]. Each of the eight HSs corresponded to a range of scores for the three factors, resulting in HSs characterised by discrete symptom profiles (with State 1 described as mild symptoms and State 8 as extremely severe symptoms) [26]. …”

Section: Methodsmentioning

confidence: 99%

“…We used the Lenert classification [26,27] to determine the type and severity of schizophrenia symptoms experienced by EuroSC patients. The Lenert classification was developed to quantify how different symptom profiles impact the quality of life of those affected by schizophrenia [26].…”

Section: Introductionmentioning

confidence: 99%

“…The Lenert classification was developed to quantify how different symptom profiles impact the quality of life of those affected by schizophrenia [26]. Briefly, this was achieved by assigning different types of schizophrenia symptoms (positive, negative and cognitive) to eight health states (HSs) encompassing the full spectrum of overall symptom severity, from mild, through moderate and severe, to extremely severe [26]. Despite being developed in the US [26], the Lenert classification may be generalisable to the European population [28].…”

Section: Introductionmentioning

confidence: 99%

“…Briefly, this was achieved by assigning different types of schizophrenia symptoms (positive, negative and cognitive) to eight health states (HSs) encompassing the full spectrum of overall symptom severity, from mild, through moderate and severe, to extremely severe [26]. Despite being developed in the US [26], the Lenert classification may be generalisable to the European population [28]. Indeed, the Lenert classification of HS and the corresponding utility weights have been used in a number of pharmacoeconomic analyses in European and non-European countries [29–34].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Healthcare resource use in schizophrenia, EuroSC findings

Millier

Horváth

Kóczián

et al. 2017

Journal of Market Access & Health Policy

View full text Add to dashboard Cite

Background: It is unclear if the burden associated with schizophrenia is affected by the type and severity of patient’s symptoms. Objective: This study aims to quantify healthcare resource use associated with different profiles of schizophrenia symptoms. Study design: Post-hoc analysis of data from a naturalistic follow-up study. Setting: Secondary psychiatric services in France, Germany and the UK. Patients: EuroSC cohort:, representative sample of 1,208 schizophrenia patients Main outcome measure: We classified patients into eight health states, according to the Lenert classification (HS1–HS8), and estimated 6-month healthcare resource use (outpatient and day clinic visits, and hospitalisations) across the health states. Results: Approximately half of the patients were classed as having mild symptoms (HS1), with around 20% experiencing moderate, predominantly negative symptoms (HS2). The remaining health states were represented by <10% of patients each. Very few patients experienced extremely severe symptoms (HS8). No health state was associated with excess utilisation across all resource types. In terms of outpatient visits, patients were estimated to see a psychiatrist most often (3.01–4.15 visits over 6 months). Hospital admission was needed in 11%(HS1) – 35%(HS8) of patients and inpatient stays were generally prolonged for all health states (39–57 days). The average number of inpatient days was highest for patients in HS8 (18.17 days), followed by patients with severe negative symptoms (HS4; 13.37 days). In other health states characterised by severe symptoms (HS5–HS7), the average number of inpatient days was approximately half of those seen for HS4 (6.09–7.66). Conclusion: While none of the symptom profiles was associated with excess resource usage, hospitalization days were highest for HS with severe, predominantly negative or extremely severe symptoms. Patients with predominantly negative, moderate or severe symptoms appeared to have a high number of psychologist visits – an interesting finding that may reflect a specific therapeutic approach to the treatment of these patients.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Healthcare resource use in schizophrenia, EuroSC findings

Millier

Horváth

Kóczián

et al. 2017

Journal of Market Access & Health Policy

View full text Add to dashboard Cite

show abstract

Health Economics and Psychiatry: The Pursuit of Efficiency

Knapp

Beecham

2010

Principles of Social Psychiatry

View full text Add to dashboard Cite

Factors associated with health‐related quality of life in long‐stay inpatients with chronic schizophrenia

Oyama¹,

Oda

Matsuo

2022

PCN Reports

View full text Add to dashboard Cite

Aim: Few studies have investigated the health-related quality of life (HRQoL) in longstay inpatients with chronic schizophrenia in Japan. This study aimed to clarify the factors associated with HRQoL among these patients.Methods: Out of 238 patients with chronic schizophrenia admitted to three hospitals, 101 inpatients provided informed consent to participate in the study. The patients' HRQoL was assessed using two instruments: the EuroQol 5 dimensions (EQ-5D) as a generic index and the Subjective Well-being Under Neuroleptic Treatment Scale, Japanese Version (SWNS-J) as a disease-specific index. We examined the factors associated with these HRQoL indices using multiple linear regression models.Results: The patients' mean age was 62.9 years, and 51.5% were female. The mean (standard deviation) EQ-5D score and SWNS-J total score were 0.776 (0.177) and 83.5 (16.5), respectively. Multiple linear regression analysis indicated that the EQ-5D score was significantly and negatively associated with the female sex, benzodiazepine use, and Drug-Induced Extrapyramidal Symptoms Scale scores.In contrast, the SWNS-J total score was significantly and negatively associated with first-generation antipsychotics use, Brief Psychiatric Rating Scale scores, Drug-Induced Extrapyramidal Symptoms Scale scores, and Global Assessment of Functioning scale scores. Conclusion:This study identified the factors associated with two HRQoL indices among long-stay inpatients with chronic schizophrenia in Japan. Although the analyses showed differences in the associated factors between the generic EQ-5D and the disease-specific SWNS-J, extrapyramidal symptoms as adverse effects of antipsychotic treatment were found to be associated with both indices.

show abstract

Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores

Cited by 102 publications

References 18 publications

Healthcare resource use in schizophrenia, EuroSC findings

Healthcare resource use in schizophrenia, EuroSC findings

Health Economics and Psychiatry: The Pursuit of Efficiency

Factors associated with health‐related quality of life in long‐stay inpatients with chronic schizophrenia

Contact Info

Product

Resources

About